B2Core Reveals Its Latest Updates: What’s New?
29.5.2023 17:00:00 EEST | Business Wire | Press release
B2Core, the premier CRM solution trusted by brokers and exchanges around the globe, continues to push the boundaries of innovation with its most recent significant update. This update introduces several advanced features and streamlined operations, giving financial institutions more powerful capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005019/en/
Telegram Integration (Graphic: Business Wire)
Let's have a look at the most notable features.
1. Advanced Event Notification Module
A brand-new Event Notification module has been added to the B2Core Back Office, providing admin users with a vast array of customizable event notifications. With the available 27 choices, administrators may send out alerts for various situations, from withdrawal requests to successful registrations.
Notifications are sent out to admin users on time whenever an event occurs, allowing them to respond appropriately. Additionally, the system allows additional admin users to be added to the "Users" category to receive notifications.
For your convenience, the module's event notification channels include email, SMS, Slack, and now Telegram. The "System-Templates" tab is where administrators may adjust settings and select a notification method. All event notifications are simply accessible via the user card, ensuring that vital information is always readily available.
For additional information on the new Event Notifications module, visit the official B2Core documentation page. In addition, there is a detailed How-To Guide and the References page covering more details.
2. Telegram Integration
B2Core now supports integration with Telegram, giving users even more channels to receive alerts. To begin getting Telegram notifications, users first must link their Telegram chat ID profile to their B2Core Back Office account, which is done in the admin's card under "System – Users – Edit user."
Users may configure the appropriate template under the "System – Templates – Telegram" section after navigating to the admin's card. It is now much easier for users to get important notifications on time by adding the Telegram channel to the Event Notifications area.
Step-by-step instructions on creating a Telegram template, activating a Telegram bot, and locating your unique chat ID may be found in our comprehensive How-to articles, ensuring a seamless onboarding process.
3. Detailed cTrader Data
B2Core's cTrader account interface, recently updated, provides an unmatched amount of depth for traders. Equity, Balance, Leverage, Credit, and Free Funds are just a few indications that users may dig into for their current accounts.
In addition, users may examine graphical representations of equity indicators across different timeframes and at different scales to gain a deeper understanding of the data. Access to real-time information on user orders and open positions and extensive historical information on performed trades and other pertinent data is also easily accessible. With this intuitive interface, investors can get all the relevant trading data they need in one convenient location.
4. Simplified Bulk Deposits to Client Accounts
In response to user feedback, the latest update introduces a new feature that simultaneously simplifies the process of depositing funds into multiple accounts. Within the "Accounts" section, the "Update Balances" window allows users to add funds to various designated accounts by uploading a CSV file containing the Email, ID, and precise amount. This streamlined process eliminates manual input, saving time and effort.
Bottom Line
B2Core's latest update cements its position as the CRM solution for brokers and exchanges. Introducing the Event Notification Module, Telegram Integration, Enhanced cTrader Data, and Simplified Bulk Deposits to Client Accounts showcase B2Core's commitment to providing a comprehensive and streamlined platform. Stay tuned for more exciting new features as B2Core continues to drive innovation in the industry!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230529005019/en/
Contact information
Artyom Goryushin
+44 2080 688 636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom